Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations. Agreement reflects both companies’ commitment to broadening access tobiologic medicines. TEL AVIV,...

June 03, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development of biosimilars, announced a collaboration with PSI CRO for the execution of a Phase 1 clinical study evaluating PB018, a proposed biosimilar to Ocrevus® (ocrelizumab), in patients with Multiple Sclerosis (MS). The randomized, double-blind, parallel-group study is designed to compare the pharmacokinetics...

May 22, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur . Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil....

December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG, our joint venture, regarding the licensing, supply, and commercialization agreement with Zydus Lifesciences Ltd. for NUFYMCO® (biosimilar ranibizumab), an interchangeable biosimilar to Lucentis®, in the United States. This strategic collaboration underlines the strength and expertise of Polpharma...

December 10, 2025 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases...

November 17, 2025 – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with...

Zurich, Switzerland – October 21, 2025 – Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration...

Polpharma Biologics is splitting its operations into two independent companies, each with a clear focus and mission.We will operate our biosimilars business out of Switzerland, under the original brand – Polpharma Biologics. We remain dedicated to developing and commercializing our pipeline of high-quality biologic medicines. We chose Switzerland, a strong biotech hub, for its proximity to our business...

Amsterdam, Gdańsk – September 2nd, 2025 – Polpharma Biologics S.A. (“Polpharma Biologics”), specialized in the development and manufacturing of biosimilars, today announced that it has signed licensing agreements with MS Pharma, a leading biosimilar production and distribution company in the Middle East and North Africa (MENA) region, for the commercialization of its biosimilar candidates vedolizumab...

Amsterdam, Gdańsk – August 5, 2025 – Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and...